Gene transfer: From concept to therapy

Current Opinion in Rheumatology

Volumn 12, Issue 3, 2000, Pages 205-210

  Pap, Thomas ^a   Gay, Renate E ^a   Gay, Steffen ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS FUSION PROTEIN;

ADENOVIRUS; APOPTOSIS; CELL ACTIVATION; GENE TARGETING; GENE TRANSFER; HUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANIMALS; APOPTOSIS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; CYTOKINES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION;

EID: 0034058301     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200005000-00008     Document Type: Review

References (50)

1. 1 Evans CH, Robbins PD, Ghivizzani SC, Herndon JH, Kang R, Bahnson AB, Barranger JA, Elders EM, Gay S, Tomaino MM, Wasko MC, Watkins SC, Whiteside TL, Glorioso JC, Lotze MT, Wright TM: Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 1996, 7:1261-1280.
2. 2 Ghivizzani SC, Lechman ER, Tio C, Mulé KM, Chada S, McCormack JE, Evans CH, Robbins PD: Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy. Gene Ther 1997, 4:977-982.
3. 3 Goldman MJ, Wilson JM: Expression of alpha v beta 5 integrin is necessary for efficient adenovirus-mediated gene transfer in the human airway. J Virol 1995, 69:5951-5958.
4. 4 Mathias P, Wickham T, Moore M, Nemerow G: Multiple adenovirus serotypes use alpha v integrins for infection. J Virol 1994, 68:6811-6814.
5. 5 Wickham TJ, Tzeng E, Shears LL, Roelvink PW, Li Y, Lee GM, Brough DE, Lizonova A, Kovesdi I: Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997, 71:8221-8229.
6. 6 Vanderkwaak TJ, Wang M, Gómez-Navarro J, Rancourt C, Dmitriev I, Krasnykh V, Barnes M, Siegal GP, Alvarez R, Curiel DT: An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 1999, 74:227-234.
7. 7 Crofford LJ, Bian H, Petruzelli LM, McDonagh KT, Roessler BJ: Adenovirus binding to cultured synoviocytes triggers signalling through the MAPK pathway and induced expression of cyclooxygenase-2 and interleukin-8. Arthritis Rheum 1999, 42 (suppl 9):S164.
8. 8 Oligino T, Ghivizzani SC, Wolfe D, Lechman ER, Krisky D, Mi Z, Evans CH, Robbins PD, Glorioso JC: Intra-articular delivery of a herpes simplex virus IL-1Ra gene vector reduces inflammation in a rabbit model of arthritis. Gene Ther 1999, 6:1713-1720. This paper reports the us of both first-and second-generation herpes simplex virus (HSV) vectors for gene transfer in arthritis. It is suggested that HSV vector systems could be used for therapeutic applications in patients with RA.
9. 9 Kaneda Y, Saeki Y, Morishita R: Gene therapy using HVJ-liposomes: the best of both worlds? Mol Med Today 1999, 5:298-303.
10. 10 Tomita T, Hashimoto H, Tomita N, Morishita R, Lee SB, Hayashida K, Nakamura N, Yonenobu K, Kaneda Y, Ochi T: In vivo direct gene transfer into articular cartilage by intraarticular injection mediated by HVJ (Sendai virus) and liposomes. Arthritis Rheum 1997, 40:901-906.
11. 11 Katayama R, Tomita T, Tsumaki N, Ochi T, Matsuno H, Morita Y, Yudoh K, Nakazawa F, Kimura T: Tagreted gene expression in human articular cartilage by direct in vivo gene transfer into SCID-HuRAg mouse. Arthritis Rheum 1999, 42 (suppl 9):S107.
12. 12 Evans CH, Robbins PD: Pathways to gene therapy in rheumatoid arthritis. Curr Opin Rheumatol 1996, 8:230-234.
13. 13 Evans CH, Ghivizzani SC, Lechman ER, Zhebao M, Jaffurs D, Robbins PD: Lessons learned from gene transfer approaches. Arthritis Research 1999, 1:21-24.
14. 14 Jorgensen C, Gay S: Gene therapy in osteoarticular diseases: where are we? Immunol Today 1998, 19:387-391. This article reviews the results from the First Workshop of the European Study Group of Gene Therapy in Osteoarticular Diseases, and summarizes potential targets for gene therapy in RA based on recent advances in understanding the pathogenesis of disease.
15. 15 Mageed RA, Adams G, Woodrow D, Podhajcer OL, Chernajovsky Y: Prevention of collagen-induced arthritis by gene delivery of soluble p75 tumour necrosis factor receptor. Gene Ther 1998, 5:1584-1592.
16. 16 Quattrocchi E, Walmsley M, Browne K, Williams RO, Marinova-Mutafchieva L, Buurman W, Butler DM, Feldmann M: Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis. J Immunol 1999, 163:1000-1009.
17. 17 Kuiper S, Joosten LA, Bendele AM, Edwards CK, Arntz OJ, Helsen MM, Van de Loo FA, Van den Berg WB: Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine 1998, 10:690-702.
18. 18 Van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, Van den Berg WB: Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen-and zymosan-induced arthritis. Arthritis Rheum 1995, 38:164-172.
19. 19 Vannier E, Miller LC, Dinarello CA: Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1992, 89:4076-4080.
20. 20 Wong HL, Costa GL, Lotze MT, Wahl SM: Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo. J Exp Med 1993, 177:775-781.
21. 21 Lubberts E, Joosten LA, Chabaud M, van den Bersselaar L, CoenendeRoo CJ, Richards CD, Miossec P, Van den Berg WB: Prevention of bone erosion in murine collagen arthritis by local interleukin-4 gene therapy. Arthritis Rheum 1999, 42 (suppl 9):S106.
22. 22 Hart PH, Ahern MJ, Smith MD, Finlay-Jones JJ: Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis. Immunology 1995, 84:536-542.
23. 23 Woods JM, Katschke KJ, Volin MV, Ruth JH, Woodruff DC, Amin MA, Connors MA, Kurata H, Arai K, Koch AE: Adenoviral interleukin(IL)-4 gene therapy improves rat adjuvant-induced arthritis. Arthritis Rheum 1999, 42 (suppl 9):S106.
24. 24 Boyle DL, Nguyen K, Zhuang S, McCormack JE, Chada S, Firestein GS: Intra-articular retroviral IL-4 gene therapy in rat adjuvant arthritis: clinical efficacy and enhanced TH2 function. Arthritis Rheum 1999, 42 (suppl 9):S106.
25. 25 Kawakami A, Eguchi K, Matsuoka N, Tsuboi M, Urayama S, Kawabe Y, Aoyagi T, Maeda K, Nagataki S: Inhibitory effects of interleukin-10 on synovial cells of rheumatoid arthritis. Immunology 1997, 91:252-259.
26. 26 Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, Feldmann M: Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996, 39:495-503.
27. 27 Isomaki P, Luukkainen R, Saario R, Toivanen P, Punnonen J: Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996, 39:386-395.
28. 28 Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, Van den Berg WB: Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997, 40:249-260.
29. 29 Müller-Ladner U, Evans CH, Franklin BN, Roberts CR, Gay RE, Robbins PD, Gay S: Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model. Arthritis Rheum 1999, 42:490-497. The authors demonstrate that the SCID mouse model of RA is a useful tool to study the effect of gene transfer on the aggressive behaviour of RA-SF. It is shown that gene transfer with the IL-10 gene inhibits the invasion of RA-SF into cartilage in this model.
30. 30 Kasama T, Strieter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL: Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 1995, 95:2868-2876.
31. 31 Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgensen C: Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 1998, 160:5213-5220.
32. 32 Ma Y, Thornton S, Duwel LE, Boivin GP, Giannini EH, Leiden JM, Bluestone JA, Hirsch R: Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer. J Immunol 1998, 161:1516-1524.
33. 33 Lechman ER, Jaffurs D, Ghivizzani SC, Gambotto A, Kovesdi I, Mi Z, Evans CH, Robbins PD: Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol 1999, 163:2202-2208. It is demonstrated that direct delivery of the viral IL-10 gene not only affects the treated joints by reducing the leukocytosis, cartilage matrix degradation, and levels of endogenous rabbit TNF-α but that an antiarthritic effect can be observed also in the contralateral control knee joints.
34. 34 Whalen JD, Lechman EL, Carlos CA, Weiss K, Kovesdi I, Glorioso JC, Robbins PD, Evans CH: Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol 1999, 162:3625-3632.
35. 35 Lubberts E, Joosten LA, Helsen MM, Van den Berg WB: Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine 1998, 10:361-369.
36. 36 Müller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, Gay S: Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996, 149:1607-1615.
37. 37 Pap T, Kuchen S, Parak W, Kunzler P, Gay RE, Gay S, Aicher WK: SV40 immortalized rheumatoid arthritis synovial fibroblasts (RA-SF) maintain their cytokine expression pattern and aggressive behavior in the SCID mouse model despite an altered TNF-alpha and IL-1 response. Arthritis Rheum 1999, 42 (suppl 9):S251.
38. 38 Pap T, Franz JK Gay RE, Gay S: Has research on lymphocytes hindered progress in rheumatoid arthritis? In Challenges in rheumatoid arthritis. Edited by Bird H, Snaith M. Oxford: Blackwell Science, 1999:61-77.
39. 39 Pap T, Müller-Ladner U, Gay RE, Gay S: Gene therapy in rheumatoid arthritis: how to target joint destruction? Arthritis Res 1999, 1:5-9.
40. 40 Pap T, Franz JK, Hummel KM, Jeisy E, Gay RE, Gay S: Activation of synovial fibroblasts in RA: lacking expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res 2000, 2:59-64.
41. 41 Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR: Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 1997, 94:10895-10900.
42. 42 Takayanagi H, Juji T, Miyazaki T, Iizuka H, Takahashi T, Isshiki M, Okada M, Tanaka Y, Koshihara Y, Oda H, Kurokawa T, Nakamura K, Tanaka S: Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest 1999, 104:137-146.
43. 43 Nawrath M, Hummel KM, Pap T, Müller-Ladner U, Gay RE, Möllíng K, Gay S: Effect of dominant negative mutants of raf-1 and c-myc on rheumatoid arthritis synovial fibroblasts in the SCID mouse model. Arthritis Rheum 1998, 41 (suppl 9):S95.
44. 44 Wakisaka S, Suzuki N, Saito N, Ochi T, Sakane T: Possible correction of abnormal rheumatoid arthritis synovial cell function by jun D transfection in vitro. Arthritis Rheum 1998, 41:470-481.
45. 45 Makarov SS, Johnston WN, Olsen JC, Watson JM, Mondal K, Rinehart C, Haskill JS: NF-kappa B as a target for anti-inflammatory gene therapy: suppression of inflammatory responses in monocytic and stromal cells by stable gene transfer of I kappa B alpha cDNA. Gene Ther 1997, 4:846-852.
46. 46 Franz JK, Pap T, Hummel KM, Nawrath M, Aicher WK, Shigeyama Y, Müller-Ladner U, Gay RE, Gay S: Expression of sentrin, a novel anti-apoptotic molecule at sites of synovial invasion in rheumatoid arthritis. Arthritis Rheum 2000, in press.
47. 47 Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K, Miyasaka N: Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med 1999, 5:760-767. The authors report that synovial cells derived from RA synovial tissue expressed p16INK4a when they were growth-inhibited, whereas this was not seen in other fibroblasts, including those derived from normal and osteoarthritis-affected synovial tissues. It is demonstrated that in vivo adenoviral gene therapy with the p16INK4a gene efficiently inhibited the pathology in an animal model of arthritis.
48. 48 Asahara H, Hasumuna T, Kobata T, Yagita H, Okumura K, Inoue H, Gay S, Sumida T, Nishioka K: Expression of Fas antigen and Fas ligand in the rheumatoid synovial tissue. Clin Immunol Immunopathol 1996, 81:27-34.
49. 49 Zhang H, Yang Y, Horton JL, Samoilova EB, Judge TA, Turka LA, Wilson JM, Chen Y: Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 1997, 100:1951-1957.
50. 50 Okamoto K, Asahara H, Kobayashi T, Matsuno H, Hasunuma T, Kobata T, Sumida T, Nishioka K: Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer. Gene Ther 1998, 5:331-338. This article explores the effect of cells transfected with human Fas ligand (hFasL) gene on proliferating human rheumatoid synovium engrafted in SCID mice and suggests that ex vivo gene transfer of FasL may represent a novel therapeutic strategy for RA.